Segment Information

12 Months Ended

Jun. 30, 2022

Segment Reporting [Abstract]

Segment Information

21. Segment Information

The Company’s chief operating decision maker, who is the Company’s Chief Executive Officer, allocates resources and assesses performance based on financial information of the Company. The CODM reviews financial information presented for each reportable segment for purposes of making operating decisions and assessing financial performance.

The Company manages and aggregates its operational and financial information in accordance with two reportable segments: BioPharma and Consumer Health. The BioPharma segment consists of the Company’s prescription products. The Consumer Health segment contains the Company’s consumer healthcare products.

During the year ended June 30, 2022, the BioPharma Segment recognized a total impairment loss of $64.6 million related to impairment of goodwill and write-down of assets due to the discontinuance of five non-core products, our Consumer Health segment recognized $10.8 million of goodwill and intangible assets write downs (see Note 8 Goodwill and Other intangible Assets).

Select financial information for these segments is as follows:

	Year Ended
	June 30,
	2022		2021
	(In thousands)
Consolidated revenue:
BioPharma	$	61,121	$	32,678
Consumer Health		35,548		32,954
Consolidated revenue	$	96,669	$	65,632

	Year Ended
	June 30,
	2022		2021
	(In thousands)
Consolidated net loss:
BioPharma	$	(92,708)	$	(50,529)
Consumer Health		(17,465)		(7,760)
Consolidated net loss	$	(110,173)	$	(58,289)

	June 30,
	2022		2021
	(In thousands)
Total assets:
BioPharma	$	121,377	$	236,449
Consumer Health		16,246		29,219
Consolidated assets	$	137,623	$	265,668